Prevention of Autoimmune Diabetes in Nonobese Diabetic Female Mice by Treatment with Recombinant Glutamic Acid Decarboxylase (GAD 65)

1995 ◽  
Vol 76 (1) ◽  
pp. 90-95 ◽  
Author(s):  
Jean-Marie Pleau ◽  
Flavia Fernandez-Saravia ◽  
Anne Esling ◽  
Françoise Homo-Delarche ◽  
Mireille Dardenne
2003 ◽  
Vol 197 (12) ◽  
pp. 1635-1644 ◽  
Author(s):  
Elmar Jaeckel ◽  
Ludger Klein ◽  
Natalia Martin-Orozco ◽  
Harald von Boehmer

Experiments in nonobese diabetic (NOD) mice that lacked expression of glutamic acid decarboxylase (GAD) in β cells have suggested that GAD represents an autoantigen essential for initiating and maintaining the diabetogenic immune response. Several attempts of inducing GAD-specific recessive tolerance to support this hypothesis have failed. Here we report on successful tolerance induction by expressing a modified form of GAD under control of the invariant chain promoter resulting in efficient epitope display. In spite of specific tolerance insulitis and diabetes occurred with normal kinetics indicating that GAD is not an essential autoantigen in the pathogenesis of diabetes.


1998 ◽  
Vol 62 (3) ◽  
pp. 123-130 ◽  
Author(s):  
Faı̈za Rharbaoui ◽  
Claude Granier ◽  
Mouna Kellou ◽  
Jean-Claude Mani ◽  
Peter van Endert ◽  
...  

2004 ◽  
Vol 50 (8) ◽  
pp. 1378-1382 ◽  
Author(s):  
Xavier Palomer ◽  
Dídac Mauricio ◽  
José Rodríguez-Espinosa ◽  
Edgar Zapico ◽  
Carme Mayoral ◽  
...  

Abstract Background: Autoantibodies for the 65-kDa form of glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase-like protein (IA-2) are measured for risk prediction and diagnosis of autoimmune diabetes mellitus. There is a lack of adequate nonisotopic alternatives to the most widely used method for both autoantibodies, which is a radiobinding assay (RBA). Methods: We compared two commercially available immunoassays, an ELISA and a time-resolved immunofluorometric assay (TR-IFMA), with RBA. Results: We found excellent agreement between the RBA and ELISA for measurement of GAD65 autoantibodies (GADAs); they showed comparable analytical precision in the cutoff range and achieved similar diagnostic specificity. The ELISA identified more GADA-positive individuals among patients with new-onset type 1 diabetes than did the RBA [89% (95% confidence interval, 78–95%), vs 71% (58–82%); P <0.03]. For IA-2 autoantibodies (IA-2As), only the TR-IFMA achieved analytical performance and diagnostic accuracy comparable to that of the RBA. These results with the GADA ELISA and IA-2A TR-IFMA were consistent with those obtained blindly in the Diabetes Antibody Standardization Program 2003. The performance of the GADA TR-IFMA and IA-2A ELISA was unsatisfactory, and these tests were not subjected to clinical evaluation. Conclusions: The GADA ELISA and IA-2A TR-IFMA behave comparably with RBA and are thus suitable for use in the clinical laboratory.


Nephron ◽  
1996 ◽  
Vol 72 (4) ◽  
pp. 662-666 ◽  
Author(s):  
Zhi-Hong Liu ◽  
Liliane J. Striker ◽  
M. Hattori ◽  
Chih-Wei Yang ◽  
Gary E. Striker

Sign in / Sign up

Export Citation Format

Share Document